Immunome, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Immunome, Inc. (IMNM) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$333.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-11
- Immunome, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was -$333.00K.
- Immunome, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was $0.00.
- Immunome, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was $0.00.
- Immunome, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $24.00K, a 64.71% decline year-over-year.
- Immunome, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2025 was -$57.00K, a 262.86% decline from fiscal 2024.
- Immunome, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was $35.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$333.00K 10-Q · filed 2026-08-11 | -$333.00K 10-Q · filed 2026-08-11 | -$333.00K derived: sum of 3 quarters · filed 2026-08-11 | -$309.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $24.00K derived: sum of 3 quarters · filed 2026-05-12 | $3.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $24.00K derived: sum of 2 quarters · filed 2026-03-03 | $3.00K derived: sum of 3 quarters · filed 2026-08-11 | -$57.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | $24.00K 10-Q · filed 2025-11-06 | $3.00K derived: sum of 2 quarters · filed 2026-08-11 | -$57.00K 10-Q · filed 2025-11-06 | -$70.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$21.00K 10-Q · filed 2026-08-11 | -$81.00K 10-Q · filed 2026-08-11 | -$94.00K derived: sum of 3 quarters · filed 2026-08-11 | -$26.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$60.00K 10-Q · filed 2026-05-12 | -$73.00K derived: sum of 2 quarters · filed 2026-05-12 | -$5.00K derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $55.00K derived: sum of 2 quarters · filed 2026-03-03 | $35.00K 10-K · filed 2026-03-03 | |
| 2024-09-30 | $68.00K 10-Q · filed 2025-11-06 | $48.00K 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |